Showing results (371-380 of 419) with videos related to

Sort By:
Pageof 42
Blood|December 23, 1999
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndromeM S Tallman, J W Andersen, C A Schiffer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patientsD J Winston, H M Lazarus, R A Beveridge, et al.
Bone Marrow Transplantation|February 5, 2008
Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcomaS L Gardner, J Carreras, C Boudreau, et al.
Leukemia|August 31, 2013
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual diseaseV Bachanova, D I Marks, M-J Zhang, et al.
Experimental Hematology|November 8, 2001
The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemiaC B Miller, P A Rowlings, M J Zhang, et al.
Bone Marrow Transplantation|December 1, 1999
Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimexJ M Rowe, A P Rapoport, D H Ryan, et al.
Blood|December 9, 2000
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group StudyM L Slovak, K J Kopecky, P A Cassileth, et al.
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Bone Marrow Transplantation|April 19, 2016
Autologous transplant remains the preferred therapy for relapsed APL in CR2C Ganzel, V Mathews, K Alimoghaddam, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)R Advani, G Visani, D Milligan, et al.
Pageof 42